https://www.openbell.ai/ 2026-09-23T11:27:18.345Z hourly 1.0 https://www.openbell.ai/support 2026-09-23T11:27:18.345Z monthly 0.7 https://www.openbell.ai/privacy 2026-09-23T11:27:18.345Z monthly 0.5 https://www.openbell.ai/terms 2026-09-23T11:27:18.345Z monthly 0.5 https://www.openbell.ai/feed.json 2026-09-23T11:27:18.345Z hourly 0.8 https://www.openbell.ai/news/VLO:1790162742148 2026-09-23T11:25:42.148Z daily 0.9 https://cdn.brandfetch.io/VLO/w/400/h/400?c=1idopYfmtR7ZKg8QMud Goldman Sachs Maintains Buy on Valero Energy, Raises Price Target to $457 Goldman Sachs analyst Neil Mehta has reiterated a Buy rating on Valero Energy (NYSE: VLO) and increased the price target from $365 to $457. This adjustment reflects a positive outlook for the company's stock performance. https://www.openbell.ai/news/WOR:1790162662694 2026-09-23T11:24:22.694Z daily 0.9 https://cdn.brandfetch.io/WOR/w/400/h/400?c=1idopYfmtR7ZKg8QMud Worthington Enterprises shares are trading higher after the company reported better-than-expected Q1 financial results. openbell Financial News https://www.openbell.ai/news/META:1790162617383 2026-09-23T11:23:37.383Z daily 0.9 https://cdn.brandfetch.io/META/w/400/h/400?c=1idopYfmtR7ZKg8QMud Keybanc Maintains Overweight on Meta Platforms, Raises Price Target to $900 Keybanc analyst Justin Patterson has maintained an Overweight rating on Meta Platforms (NASDAQ: META) and raised the price target from $780 to $900. This adjustment reflects a positive outlook on the company's performance. https://www.openbell.ai/news/CBRL:1790162585380 2026-09-23T11:23:05.380Z daily 0.9 https://cdn.brandfetch.io/CBRL/w/400/h/400?c=1idopYfmtR7ZKg8QMud Cracker Barrel Old Lowers FY2027 Sales Guidance from $3.800B-$3.900B to $3.325B-$3.400B vs $3.386B Est Cracker Barrel Old (NASDAQ: CBRL) has revised its fiscal year 2027 sales guidance, lowering it from a range of $3.800 billion-$3.900 billion to $3.325 billion-$3.400 billion. This new guidance is below the market estimate of $3.386 billion. https://www.openbell.ai/news/IONQ:1790162476508 2026-09-23T11:21:16.508Z daily 0.9 https://cdn.brandfetch.io/IONQ/w/400/h/400?c=1idopYfmtR7ZKg8QMud Market-Moving News for September 23rd IonQ shares increased by 14% following the announcement of a breakthrough in quantum computing, where researchers developed the first end-to-end real-time quantum error correction decoder that operates on a standard CPU. TriSalus Life Sciences also saw a 32% rise in its stock after receiving FDA 510(k) clearance for its TriNav Advance product. In contrast, Voyager Technologies experienced a 10% decline in shares due to the announcement of a $350 million offering of convertible senior notes. https://www.openbell.ai/news/CBRL:1790162158904 2026-09-23T11:15:58.904Z daily 0.9 https://cdn.brandfetch.io/CBRL/w/400/h/400?c=1idopYfmtR7ZKg8QMud Cracker Barrel Old Q4 Adj. EPS $0.99 Beats $0.15 Estimate, Sales $849.342M Beat $836.894M Estimate Cracker Barrel Old (NASDAQ: CBRL) reported Q4 adjusted earnings per share of $0.99, significantly exceeding the analyst estimate of $0.15 by 560%. This represents a 33.78% increase from $0.74 per share in the same quarter last year. The company's quarterly sales reached $849.342 million, surpassing the estimate of $836.894 million by 1.49%, although this reflects a 2.15% decline from $868.009 million in the previous year. https://www.openbell.ai/news/TEL:1790162029903 2026-09-23T11:13:49.903Z daily 0.9 https://cdn.brandfetch.io/TEL/w/400/h/400?c=1idopYfmtR7ZKg8QMud Bernstein Initiates Coverage On TE Connectivity with Outperform Rating, Announces Price Target of $243 Bernstein analyst Varun Govindaraj has initiated coverage on TE Connectivity (NYSE: TEL) with an Outperform rating. The firm has set a price target of $243 for the stock. https://www.openbell.ai/news/APH:1790161965925 2026-09-23T11:12:45.925Z daily 0.9 https://cdn.brandfetch.io/APH/w/400/h/400?c=1idopYfmtR7ZKg8QMud Bernstein Initiates Coverage On Amphenol with Outperform Rating, Announces Price Target of $99 Bernstein analyst Varun Govindaraj has initiated coverage on Amphenol (NYSE: APH) with an Outperform rating. The analyst has set a price target of $99 for the company's stock. https://www.openbell.ai/news/BMEA:1790161861656 2026-09-23T11:11:01.656Z daily 0.9 https://cdn.brandfetch.io/BMEA/w/400/h/400?c=1idopYfmtR7ZKg8QMud Biomea Fusion Terminates Proposed Public Offering Of Securities Due To Market Conditions Biomea Fusion, Inc. has terminated its proposed public offering of securities, initially announced on September 22, 2026, due to unfavorable market conditions. The company's management determined that the current environment would not allow for an offering that would benefit stockholders. No securities were sold in connection with this proposed offering, which was based on a shelf registration statement filed with the SEC on August 5, 2025. https://www.openbell.ai/news/PATH:1790161861064 2026-09-23T11:11:01.064Z daily 0.9 https://cdn.brandfetch.io/PATH/w/400/h/400?c=1idopYfmtR7ZKg8QMud Needham Reiterates Buy on UiPath, Maintains $22 Price Target Needham analyst Scott Berg has reiterated a 'Buy' rating on UiPath (NYSE: PATH) and has maintained a price target of $22 for the stock. This endorsement reflects confidence in the company's performance and potential in the market. https://www.openbell.ai/news/CTSH:1790161843106 2026-09-23T11:10:43.106Z daily 0.9 https://cdn.brandfetch.io/CTSH/w/400/h/400?c=1idopYfmtR7ZKg8QMud Cognizant And Cognition Announce That Autonomous AI Software Engineer, Devin, Helped Yield A 37% Percent Net Cost Saving On A Fixed Budget And Accelerated Timeline Cognizant and Cognition have collaborated since 2024, launching an AI engineering partnership in January 2026, utilizing the AI software engineer Devin to enhance engineering capacity. Devin has achieved a 37% net cost saving for Odyssey Logistics on a fixed budget and accelerated delivery timelines, with delivery throughput increasing by approximately one-third. The partnership has resulted in a suite of offerings, including modernization, quality engineering, and cyber defense solutions, and both companies plan to expand their collaborative efforts in various areas. https://www.openbell.ai/news/ARMP:1790161786353 2026-09-23T11:09:46.353Z daily 0.9 https://cdn.brandfetch.io/ARMP/w/400/h/400?c=1idopYfmtR7ZKg8QMud Armata Pharmaceuticals Receives Additional $3.7M In Non-dilutive Funds From US Department Of War For Phase 3 Development Program For AP-SA02 Armata Pharmaceuticals has secured an additional $3.7 million in non-dilutive funding from the U.S. Department of War for the Phase 3 development of its lead clinical candidate, AP-SA02, which targets complicated Staphylococcus aureus bacteremia. This funding is part of a larger award that now totals approximately $32.4 million, reflecting the government's ongoing support for the program. AP-SA02 is being developed as an adjunctive treatment for infections caused by both methicillin-sensitive and methicillin-resistant strains of S. aureus, with a Phase 3 study expected to begin in the second half of 2026. https://www.openbell.ai/news/REA:1790161763800 2026-09-23T11:09:23.800Z daily 0.9 https://cdn.brandfetch.io/REA/w/400/h/400?c=1idopYfmtR7ZKg8QMud Rare Earths Americas Says Initial Drilling At Brazil's Homer-A Project Shows Near-Surface Rare Earth Mineralization; Doubles Drill Fleet To Four Rigs openbell Financial News https://www.openbell.ai/news/ORKA:1790161714366 2026-09-23T11:08:34.366Z daily 0.9 https://cdn.brandfetch.io/ORKA/w/400/h/400?c=1idopYfmtR7ZKg8QMud Oruka Therapeutics Announces Week 28 Results From Its EVERLAST-A Phase 2A Trial Of ORKA-001 In Moderate-To-Severe Plaque Psoriasis; ORKA-001 Maintained Favorable Safety And Tolerability Profile Through Week 28; 16-Week EVERLAST-B Data Expected In Q4 2026 Oruka Therapeutics reported Week 28 results from its EVERLAST-A Phase 2a trial of ORKA-001, a monoclonal antibody for moderate-to-severe plaque psoriasis, showing a PASI 100 response rate of 71.4% among treated patients. The trial, involving 84 patients, demonstrated a favorable safety profile, with the only notable adverse event being an upper respiratory tract infection in 8% of patients. Oruka plans to release full 52-week data later this year and is advancing the EVERLAST-B Phase 2b trial, with results expected in Q4 2026. https://www.openbell.ai/news/KIDZ:1790161710012 2026-09-23T11:08:30.012Z daily 0.9 https://cdn.brandfetch.io/KIDZ/w/400/h/400?c=1idopYfmtR7ZKg8QMud KIDZ AI Announces It Joined Open Compute Project To Advance Enterprise GPU Cloud Deployment openbell Financial News https://www.openbell.ai/news/TVTX:1790161644027 2026-09-23T11:07:24.027Z daily 0.9 https://cdn.brandfetch.io/TVTX/w/400/h/400?c=1idopYfmtR7ZKg8QMud Travere Therapeutics Says USPTO Allowed Patent For FILSPARI In FSGS, Expected To Provide Coverage Into October 2037 openbell Financial News https://www.openbell.ai/news/BBY:1790161599805 2026-09-23T11:06:39.805Z daily 0.9 https://cdn.brandfetch.io/BBY/w/400/h/400?c=1idopYfmtR7ZKg8QMud Best Buy And Amazon Announce Expanded Multiyear Fire TV Partnership, With Best Buy Ads Offering Fire TV Ad Inventory On Insignia TVs openbell Financial News https://www.openbell.ai/news/GIS:1790161584330 2026-09-23T11:06:24.330Z daily 0.9 https://cdn.brandfetch.io/GIS/w/400/h/400?c=1idopYfmtR7ZKg8QMud General Mills Chairman And CEO Jeff Harmening Reaffirms Confidence In Fiscal 2027 Guidance, Cites Industry-Leading Cost Savings Through Holistic Margin Management And Global Transformation Initiative General Mills Chairman and CEO Jeff Harmening expressed confidence in the company's fiscal 2027 guidance, highlighting improved topline performance driven by product innovation. The company is achieving industry-leading cost savings through its Holistic Margin Management program and a global Transformation initiative. Harmening emphasized that their disciplined execution in a volatile environment supports their optimistic outlook for fiscal 2027. https://www.openbell.ai/news/ACIU:1790161534343 2026-09-23T11:05:34.343Z daily 0.9 https://cdn.brandfetch.io/ACIU/w/400/h/400?c=1idopYfmtR7ZKg8QMud AC Immune Announces Safety And Immunogenicity Results Through Week 100 In Part 1 Of VacSYn, Its Phase 2 Trial Of ACI-7104 In Patients With Early-Stage Parkinson’s Disease: All Primary Endpoints Were Met, Generally Safe And Well Tolerated; Strong Immunogenicity Demonstrated, With 100% Response Rate After Three Immunizations AC Immune SA (NASDAQ: ACIU) announced positive results from Part 1 of its Phase 2 trial, VacSYn, for ACI-7104 in early-stage Parkinson's disease patients, meeting all primary endpoints of safety, tolerability, and immunogenicity. The trial showed ACI-7104 was generally safe and well-tolerated, with a 100% response rate in antibody development after three immunizations. Preliminary evidence suggests potential target engagement with observed trends in biomarker correlations, and the trial is set to continue into Part 2, with FDA submission planned for early 2027. https://www.openbell.ai/news/IMVT:1790161511752 2026-09-23T11:05:11.752Z daily 0.9 https://cdn.brandfetch.io/IMVT/w/400/h/400?c=1idopYfmtR7ZKg8QMud Roivant And Immunovant Say Topline Results From Period 1 Of Proof-of-concept Trial of IMVT-1402 (Imeroprubart) For Cutaneous Lupus Erythematosus Did Not Achieve Statistical Significance On The Primary Endpoint Immunovant's proof-of-concept trial for IMVT-1402 (imeroprubart) in cutaneous lupus erythematosus did not achieve statistical significance on its primary endpoint, the CLASI-A percent change from baseline at Week 12. While positive trends were noted in multiple endpoints and the drug showed a favorable safety profile, the results did not meet the company's criteria to continue development in this indication. All other clinical development timelines for Immunovant remain on track. https://www.openbell.ai/news/CTSO:1790161406615 2026-09-23T11:03:26.615Z daily 0.9 https://cdn.brandfetch.io/CTSO/w/400/h/400?c=1idopYfmtR7ZKg8QMud CytoSorbents Regains Nasdaq Compliance CytoSorbents Corporation (NASDAQ: CTSO) has regained compliance with the Nasdaq Stock Market's minimum bid price requirement of $1.00 per share. The company specializes in blood purification treatments for critical conditions in intensive care and cardiac surgery. https://www.openbell.ai/news/MANU:1790161387784 2026-09-23T11:03:07.784Z daily 0.9 https://cdn.brandfetch.io/MANU/w/400/h/400?c=1idopYfmtR7ZKg8QMud Manchester United Q4 Adj. EPS $(0.22) Misses $(0.03) Estimate, Sales $211.275M Beat $145.000M Estimate Manchester United (NYSE: MANU) reported Q4 adjusted earnings per share of $(0.22), missing the analyst estimate of $(0.03) by 633.33%. This marks a 450% increase in losses compared to $(0.04) per share from the same period last year. However, the company achieved quarterly sales of $211.275 million, exceeding the $145.000 million estimate by 45.71%, despite a 3.55% decrease from $219.042 million in the previous year. https://www.openbell.ai/news/PBM:1790161348732 2026-09-23T11:02:28.732Z daily 0.9 https://cdn.brandfetch.io/PBM/w/400/h/400?c=1idopYfmtR7ZKg8QMud Psyence Biomedical Agrees To Make Cash Investment Of Up To $5M In Psyence Labs Psyence Biomedical Ltd. has agreed to invest up to $5 million in Psyence Labs Ltd., with $2.4 million already committed, to enhance scientific and manufacturing capabilities for its planned ibogaine clinical trial in Texas for Opioid Use Disorder. Additionally, the two companies will engage in a value-matched share exchange valued at approximately $9 million each. Psyence has established the Texas Ibogaine Research Corporation to coordinate its U.S. regulatory and clinical activities related to ibogaine. The company is currently assessing the feasibility of the clinical trial, which will require regulatory approvals and other customary requirements. https://www.openbell.ai/news/PALI:1790161291098 2026-09-23T11:01:31.098Z daily 0.9 https://cdn.brandfetch.io/PALI/w/400/h/400?c=1idopYfmtR7ZKg8QMud HC Wainwright & Co. Reiterates Buy on Palisade Bio, Maintains $7 Price Target HC Wainwright & Co. analyst Mitchell S. Kapoor has reiterated a Buy rating on Palisade Bio (NASDAQ: PALI) and maintained a price target of $7 for the stock. https://www.openbell.ai/news/TSX:AGF:1790161238761 2026-09-23T11:00:38.761Z daily 0.9 https://cdn.brandfetch.io/TSX:AGF/w/400/h/400?c=1idopYfmtR7ZKg8QMud AGF Management Q3 Adj. EPS $0.49, Sales $112.500M AGF Management reported a third-quarter adjusted earnings per share (EPS) of $0.49 and sales of $112.500 million. The results reflect the company's performance for the quarter, as indicated by the financial figures. https://www.openbell.ai/news/COLL:1790161179206 2026-09-23T10:59:39.206Z daily 0.9 https://cdn.brandfetch.io/COLL/w/400/h/400?c=1idopYfmtR7ZKg8QMud Oppenheimer Initiates Coverage On Collegium Pharmaceutical with Outperform Rating, Announces Price Target of $50 Oppenheimer analyst Les Sulewski has initiated coverage on Collegium Pharmaceutical (NASDAQ: COLL) with an Outperform rating. The firm has set a price target of $50 for the stock. https://www.openbell.ai/news/ABSI:1790161164247 2026-09-23T10:59:24.247Z daily 0.9 https://cdn.brandfetch.io/ABSI/w/400/h/400?c=1idopYfmtR7ZKg8QMud Needham Reiterates Buy on Absci, Maintains $11 Price Target Needham analyst Gil Blum has reiterated a Buy rating on Absci (NASDAQ: ABSI) and has maintained a price target of $11 for the stock. https://www.openbell.ai/news/RCL:1790161024494 2026-09-23T10:57:04.494Z daily 0.9 https://cdn.benzinga.com/files/images/story/2026/09/23/Royal-Caribbean-Cruise-Ship-In-Cape-Cana.jpg?width=250&height=187 Royal Caribbean Sets Sights on $2 Trillion Vacation Market With Sandals Investment Royal Caribbean Group has agreed to invest approximately $3 billion for a 50% stake in Sandals and Beaches Resorts, aiming to expand into the all-inclusive resort market and enhance its presence in the $2 trillion global vacation market. The acquisition, expected to close in early 2027, will be financed through debt from Morgan Stanley and is projected to boost earnings next year. Following the investment, Royal Caribbean's stock rose 1.81% to $239.15 in premarket trading. https://www.openbell.ai/news/ANIP:1790161010421 2026-09-23T10:56:50.421Z daily 0.9 https://cdn.brandfetch.io/ANIP/w/400/h/400?c=1idopYfmtR7ZKg8QMud ANI Pharmaceuticals Receives Final FDA Approval Of Its Abbreviated New Drug Application For Everolimus Tablets For Oral Suspension ANI Pharmaceuticals has received final FDA approval for its generic version of Everolimus Tablets for Oral Suspension in 2mg, 3mg, and 5mg dosages. The U.S. annual sales for the reference drug, Afinitor Disperz®, are approximately $123 million, according to July 2026 IQVIA data. ANI's CEO, Nikhil Lalwani, highlighted the approval as a testament to the R&D team's capabilities and indicated plans to launch at least 15 new generics this year. https://www.openbell.ai/news/META:1790160581983 2026-09-23T10:49:41.983Z daily 0.9 https://cdn.brandfetch.io/META/w/400/h/400?c=1idopYfmtR7ZKg8QMud Cantor Fitzgerald Maintains Overweight on Meta Platforms, Raises Price Target to $860 Cantor Fitzgerald analyst Deepak Mathivanan has maintained an Overweight rating on Meta Platforms (NASDAQ: META) and raised the price target from $680 to $860. This adjustment reflects a positive outlook on the company's performance. https://www.openbell.ai/news/RPM:1790160523396 2026-09-23T10:48:43.396Z daily 0.9 https://cdn.brandfetch.io/RPM/w/400/h/400?c=1idopYfmtR7ZKg8QMud RPM International Agrees To Acquire Volteco; Terms Not Disclosed RPM International Inc. has signed a definitive agreement to acquire Volteco S.p.A., an Italian supplier of below-grade waterproofing solutions, to enhance its Tremco Construction Products Group. The terms of the acquisition have not been disclosed, and the transaction is anticipated to close in the second quarter of fiscal 2027, pending customary closing conditions. https://www.openbell.ai/news/ENHA:1790160492853 2026-09-23T10:48:12.853Z daily 0.9 https://cdn.brandfetch.io/ENHA/w/400/h/400?c=1idopYfmtR7ZKg8QMud Cantor Fitzgerald Initiates Coverage On Enhanced Group with Overweight Rating, Announces Price Target of $4 Cantor Fitzgerald analyst Gabie Ingoglia has initiated coverage on Enhanced Group (NYSE: ENHA) with an Overweight rating. The firm has set a price target of $4 for the stock. https://www.openbell.ai/news/BDC:1790160380618 2026-09-23T10:46:20.618Z daily 0.9 https://cdn.brandfetch.io/BDC/w/400/h/400?c=1idopYfmtR7ZKg8QMud Needham Initiates Coverage On Belden with Buy Rating, Announces Price Target of $140 Needham analyst Fraser Jamieson has initiated coverage on Belden (NYSE: BDC) with a Buy rating. The firm has set a price target of $140 for the company's stock. https://www.openbell.ai/news/ENTA:1790160305064 2026-09-23T10:45:05.064Z daily 0.9 https://cdn.brandfetch.io/ENTA/w/400/h/400?c=1idopYfmtR7ZKg8QMud HC Wainwright & Co. Reiterates Buy on Enanta Pharma, Maintains $20 Price Target HC Wainwright & Co. analyst Brandon Folkes has reiterated a Buy rating on Enanta Pharma (NASDAQ: ENTA) and maintained a price target of $20. This endorsement suggests confidence in the company's future performance. https://www.openbell.ai/news/TLSI:1790160209921 2026-09-23T10:43:29.921Z daily 0.9 https://cdn.brandfetch.io/TLSI/w/400/h/400?c=1idopYfmtR7ZKg8QMud HC Wainwright & Co. Maintains Buy on TriSalus Life Sciences, Raises Price Target to $12 HC Wainwright & Co. analyst Swayampakula Ramakanth has maintained a Buy rating on TriSalus Life Sciences (NASDAQ: TLSI) and raised the price target from $11 to $12. https://www.openbell.ai/news/ONON:1790160133112 2026-09-23T10:42:13.112Z daily 0.9 https://cdn.brandfetch.io/ONON/w/400/h/400?c=1idopYfmtR7ZKg8QMud Needham Maintains Buy on On Holding, Raises Price Target to $40 Needham analyst Tom Nikic has maintained a Buy rating on On Holding (NYSE: ONON) and increased the price target from $37 to $40. This adjustment reflects a positive outlook on the company's performance. https://www.openbell.ai/news/GOOGL:1790159844473 2026-09-23T10:37:24.473Z daily 0.9 https://cdn.benzinga.com/files/images/story/2026/09/23/Paris--France---June-16--2023-Elon-Musk-.jpg?width=250&height=187 Elon Musk Says AI Could ‘Beat All Fields’ By 2028, Far Faster Than François Chollet’s 10-20 Year Forecast Elon Musk predicts that artificial intelligence could surpass all fields by 2028, significantly shortening a previous forecast by AI researcher François Chollet, who estimated a 10-20 year timeline for AI's dominance in science. Musk's assertion follows a recent trend of AI advancements, including Anthropic's optimization of biomolecular models and Google DeepMind's use of AI agents for scientific hypothesis generation. Additionally, Musk's companies are actively developing AI tools, with SpaceXAI releasing Grok 4.7 and training Grok 5 on engineering data. https://www.openbell.ai/news/ITRG:1790159811532 2026-09-23T10:36:51.532Z daily 0.9 https://cdn.brandfetch.io/ITRG/w/400/h/400?c=1idopYfmtR7ZKg8QMud Integra Resources Announce Additional Results From its Drill Program At The Florida Canyon Mine In Nevada; Data Continue To Demonstrate Potential To Further Expand The Established Gold Resource Integra Resources has announced additional drill results from its Florida Canyon Mine in Nevada, indicating potential for further gold resource expansion. The ongoing drill program has completed 30,140 meters in 2026, revealing promising results from the Madre Shear North Target and Inter-Pit areas, with notable grades such as 1.30 g/t Au over 62.5 m. The updated Technical Report highlighted a 74% increase in Mineral Reserves, and the company plans to explore targets outside the mine footprint, including 7,000 meters of drilling at the Standard Mine area. https://www.openbell.ai/news/ORIC:1790159780361 2026-09-23T10:36:20.361Z daily 0.9 https://cdn.brandfetch.io/ORIC/w/400/h/400?c=1idopYfmtR7ZKg8QMud BTIG Initiates Coverage On ORIC Pharmaceuticals with Buy Rating, Announces Price Target of $26 BTIG analyst Jeet Mukherjee has initiated coverage on ORIC Pharmaceuticals (NASDAQ: ORIC) with a Buy rating. The firm has set a price target of $26 for the stock. https://www.openbell.ai/news/GIB:1790159692559 2026-09-23T10:34:52.559Z daily 0.9 https://cdn.brandfetch.io/GIB/w/400/h/400?c=1idopYfmtR7ZKg8QMud CGI Enters Strategic Partnership With D-Wave Quantum Promote Adoption Of Enterprise Quantum Capabilities CGI has entered a strategic partnership with D-Wave Quantum to promote the adoption of quantum computing technologies across various industries, including logistics, transportation, and retail. This partnership builds on over a year of collaboration and will integrate D-Wave's quantum computing platforms into CGI's advanced technology services portfolio. The focus will be on developing quantum-enabled solutions for challenges such as industrial production planning and supply chain optimization, aiming to deliver measurable business outcomes as quantum technologies mature. https://www.openbell.ai/news/AVEX:1790159666681 2026-09-23T10:34:26.681Z daily 0.9 https://cdn.brandfetch.io/AVEX/w/400/h/400?c=1idopYfmtR7ZKg8QMud AEVEX Announces Specter, New Jet‑Powered Autonomous Platform AEVEX Corp. (NYSE: AVEX) has announced the development of Specter, a new jet-powered autonomous platform designed to address emerging mission needs with a modular design and scalable manufacturing approach in collaboration with Divergent. This platform aims to enhance AEVEX's unmanned systems portfolio by providing a high-speed, turbojet-powered one-way attack capability suitable for challenging operational environments. https://www.openbell.ai/news/WIX:1790159654442 2026-09-23T10:34:14.442Z daily 0.9 https://cdn.brandfetch.io/WIX/w/400/h/400?c=1idopYfmtR7ZKg8QMud Needham Maintains Buy on Wix.com, Raises Price Target to $95 Needham analyst Bernie McTernan has maintained a Buy rating on Wix.com (NASDAQ: WIX) and increased the price target from $80 to $95. This adjustment reflects a positive outlook on the company's performance. https://www.openbell.ai/news/PCRX:1790159584339 2026-09-23T10:33:04.339Z daily 0.9 https://cdn.brandfetch.io/PCRX/w/400/h/400?c=1idopYfmtR7ZKg8QMud Oppenheimer Initiates Coverage On Pacira BioSciences with Outperform Rating, Announces Price Target of $32 Oppenheimer analyst Les Sulewski has initiated coverage on Pacira BioSciences (NASDAQ: PCRX) with an Outperform rating. The firm has set a price target of $32 for the company's stock. https://www.openbell.ai/news/RBLX:1790159569269 2026-09-23T10:32:49.269Z daily 0.9 https://cdn.brandfetch.io/RBLX/w/400/h/400?c=1idopYfmtR7ZKg8QMud Needham Maintains Buy on Roblox, Raises Price Target to $55 Needham analyst Bernie McTernan has maintained a 'Buy' rating on Roblox (NYSE: RBLX) and increased the price target from $50 to $55. This adjustment reflects a positive outlook on the company's performance. https://www.openbell.ai/news/CRMD:1790159510813 2026-09-23T10:31:50.813Z daily 0.9 https://cdn.brandfetch.io/CRMD/w/400/h/400?c=1idopYfmtR7ZKg8QMud Oppenheimer Initiates Coverage On Cormedix with Outperform Rating, Announces Price Target of $15 Oppenheimer analyst Les Sulewski has initiated coverage on Cormedix (NASDAQ: CRMD) with an Outperform rating. The firm has set a price target of $15 for the company's stock. https://www.openbell.ai/news/PLSE:1790159246371 2026-09-23T10:27:26.371Z daily 0.9 https://cdn.brandfetch.io/PLSE/w/400/h/400?c=1idopYfmtR7ZKg8QMud BTIG Initiates Coverage On Pulse Biosciences with Buy Rating, Announces Price Target of $70 BTIG analyst Marie Thibault has initiated coverage on Pulse Biosciences (NASDAQ: PLSE) with a Buy rating. The firm has set a price target of $70 for the company's stock. https://www.openbell.ai/news/COST:1790159151790 2026-09-23T10:25:51.790Z daily 0.9 https://cdn.brandfetch.io/COST/w/400/h/400?c=1idopYfmtR7ZKg8QMud BTIG Reiterates Buy on Costco Wholesale, Maintains $1125 Price Target BTIG analyst Robert Drbul has reiterated a Buy rating on Costco Wholesale (NASDAQ: COST) and maintained a price target of $1125 for the stock. This endorsement reflects confidence in Costco's performance and market position. https://www.openbell.ai/news/SMCI:1790159093254 2026-09-23T10:24:53.254Z daily 0.9 https://cdn.benzinga.com/files/images/story/2026/09/23/Supermicro-Logo.jpg?width=250&height=187 What's Going On With Super Micro Computer Stock Wednesday? Super Micro Computer Inc. (NASDAQ: SMCI) stock rose approximately 1% in premarket trading, reaching $41.96, as traders responded to improving risk appetite and the company's strong momentum in AI infrastructure demand. The company has a $60 billion order book and projects fiscal 2027 revenues between $65 billion and $72 billion, with a potential $2 trillion to $4 trillion addressable market in AI infrastructure. Analysts maintain a Hold rating with an average price target of $39.50, while the stock is currently trading 32% above its 200-day moving average but down 11.6% over the past year. https://www.openbell.ai/news/NKE:1790159001351 2026-09-23T10:23:21.351Z daily 0.9 https://cdn.brandfetch.io/NKE/w/400/h/400?c=1idopYfmtR7ZKg8QMud BTIG Reiterates Buy on Nike, Maintains $55 Price Target BTIG analyst Robert Drbul has reiterated a Buy rating on Nike (NYSE: NKE) and has maintained a price target of $55 for the stock. https://www.openbell.ai/news/NICE:1790158835819 2026-09-23T10:20:35.819Z daily 0.9 https://cdn.brandfetch.io/NICE/w/400/h/400?c=1idopYfmtR7ZKg8QMud Sky News Reported Brookfield In Advanced Talks To Buy Actimize From NICE For About $2B Brookfield is in advanced negotiations to acquire Actimize from NICE for approximately $2 billion. This potential deal indicates Brookfield's strategy to expand its portfolio in the financial technology sector. The acquisition could significantly impact NICE's financial standing and market position.